Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2024:
- 207,500 shares
- €353,960.14
- On the buy side: 2,075,591 shares for a total amount of €8,893,798.52
- On the sell side: 1,999,091 shares for a total amount of €8,546,873.15
- On the buy side: 2,752
- On the sell side: 2,582
- 27, 911 shares
- €769,849.43
GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor1) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, in relation to GENFIT's research and development programs. The use of certain words, including "believe”, "potential,” "expect”, "target”, "may” and "will” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2023 Universal Registration Document filed on April 5, 2024 (no. D.24-0246) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's 2023 Annual Report on Form 20-F filed with the SEC on April 5, 2024 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.
CONTACTS
GENFIT | Investors
Tel: +33 3 2016 4000 | [email protected]
PRESS RELATIONS | Media
Stephanie Boyer - Press relations | Tel: +333 2016 4000 | [email protected]
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com
APPENDIX
H2 2024
| Buy side | Sell side | |||||
| Date | Number of executions | Number of shares | Traded amounts in EUR | Number of executions | Number of shares | Traded amounts in EUR |
| TOTAL | 2 752 | 2 075 591 | 8 893 798,52 | 2 582 | 1 999 091 | 8 546 873,15 |
| 01/07/2024 | 6 | 2001 | 7 303,53 | 27 | 23 000 | 84 574,91 |
| 02/07/2024 | 22 | 24486 | 90 640,07 | 29 | 35 435 | 132 089,99 |
| 03/07/2024 | 27 | 30939 | 114 380,86 | 33 | 71 378 | 267 007,25 |
| 04/07/2024 | 11 | 13001 | 51 663,89 | 42 | 51 221 | 201 406,61 |
| 05/07/2024 | 76 | 130000 | 511 275,70 | 57 | 61 233 | 244 186,18 |
| 08/07/2024 | 41 | 38897 | 151 285,60 | 55 | 77 768 | 305 129,75 |
| 09/07/2024 | 37 | 43587 | 176 002,45 | 9 | 12928 | 52712,47 |
| 10/07/2024 | 25 | 19013 | 74 870,39 | 17 | 29 144 | 116 282,19 |
| 11/07/2024 | 14 | 19855 | 79 675,90 | 24 | 34 636 | 140 647,14 |
| 12/07/2024 | 54 | 39000 | 159 246,75 | 12 | 15 601 | 63 635,70 |
| 15/07/2024 | 22 | 30425 | 125 035,49 | 26 | 27 840 | 115 579,99 |
| 16/07/2024 | 24 | 17501 | 72 881,51 | 23 | 29 825 | 123 879,63 |
| 17/07/2024 | 41 | 24001 | 100 374,10 | 13 | 13 463 | 56 731,20 |
| 18/07/2024 | 27 | 27001 | 113 194,13 | 24 | 21 843 | 91 658,25 |
| 19/07/2024 | 64 | 80377 | 325 742,26 | 14 | 4 701 | 19 124,19 |
| 22/07/2024 | 18 | 11578 | 47 447,92 | 40 | 41 101 | 167 583,98 |
| 23/07/2024 | 31 | 22655 | 90 992,22 | 12 | 4 466 | 18 016,60 |
| 24/07/2024 | 46 | 31000 | 123 816,48 | 27 | 29 786 | 118 749,93 |
| 25/07/2024 | 17 | 15068 | 59 955,12 | 36 | 24 916 | 100 006,84 |
| 26/07/2024 | 37 | 47001 | 191 976,99 | 28 | 29 289 | 120 740,39 |
| 29/07/2024 | 16 | 17454 | 71 026,43 | 40 | 28 266 | 115 827,28 |
| 30/07/2024 | 10 | 6022 | 24 353,81 | 8 | 3 907 | 15 902,90 |
| 31/07/2024 | 32 | 12888 | 51 668,12 | 9 | 3 003 | 12 178,31 |
| 01/08/2024 | 25 | 5485 | 22 139,98 | 12 | 9 901 | 40 186,97 |
| 02/08/2024 | 23 | 16442 | 63 462,01 | 3 | 3 026 | 11 609,37 |
| 05/08/2024 | 37 | 30384 | 110 456,47 | 34 | 29 384 | 106 272,82 |
| 06/08/2024 | 4 | 2501 | 9 253,65 | 7 | 12 501 | 46 653,61 |
| 07/08/2024 | 8 | 7501 | 28 378,83 | 9 | 8 417 | 32 071,21 |
| 08/08/2024 | 7 | 5001 | 18 853,77 | 1 | 1 | 3,8 |
| 09/08/2024 | 10 | 13417 | 50 264,64 | 7 | 7 501 | 28 553,76 |
| 12/08/2024 | 2 | 2501 | 9 228,72 | 7 | 8 001 | 29 858,69 |
| 13/08/2024 | 29 | 9212 | 34 354,50 | 15 | 13 123 | 49 281,59 |
| 14/08/2024 | 23 | 15001 | 57 091,26 | 24 | 21 585 | 82 604,72 |
| 15/08/2024 | 25 | 11739 | 44 362,74 | 30 | 15 805 | 60 242,34 |
| 16/08/2024 | 6 | 5790 | 22 426,58 | 26 | 24 328 | 95 234,63 |
| 19/08/2024 | 15 | 13592 | 52 667,91 | 18 | 6 059 | 23 525,58 |
| 20/08/2024 | 4 | 3435 | 13 433,94 | 17 | 14 935 | 58 413,47 |
| 21/08/2024 | 9 | 6567 | 25 786,31 | 26 | 24 001 | 95 280,85 |
| 22/08/2024 | 15 | 20001 | 78 653,93 | 8 | 5 231 | 20 573,68 |
| 23/08/2024 | 11 | 7501 | 29 241,37 | 15 | 12 271 | 48 021,70 |
| 26/08/2024 | 16 | 7174 | 28 039,51 | 8 | 3 501 | 13 766,46 |
| 27/08/2024 | 27 | 8828 | 34 423,37 | 6 | 3 501 | 13 766,42 |
| 28/08/2024 | 41 | 20771 | 80 264,34 | 13 | 7 271 | 28 326,29 |
| 29/08/2024 | 5 |
| ||||